登录新浪财经APP 搜索【信披】查看更多考评等级 一、本次员工持股计划基本情况 中重科技（天津）股份有限公司（以下简称"公司"或"中重科技"）于2025年12月10日召开第二届董事会 第十一次会议，并于2026年1月8日召开2026年第一次临时股东会，审议通过了《关于〈中重科技(天津) 股份有限公司2025年员工持股计划（草案）〉及其摘要的议案》《关于〈中重科技(天津)股份有限公司 2025年员工持股计划管理办法〉的议案》，同意公司实施2025年员工持股计划（以下简称"本员工持股 计划"或"本次员工持股计划"）。 公司本次员工持股计划的股票来源为公司回购专用证券账户回购的中重科技A股普通股股票。本次员工 持股计划拟持有的标的股票数量不超过496.64万股，本员工持股计划设立时资金总额不超过2,413.68万 元，以"份"作为认购单位，每份份额为1.00元，本员工持股计划的份额上限为2,413.68万份。初始设立 时持有人总人数不超过126人（不含预留份额），具体参加人数根据员工实际认购情况确定。本次员工 持股计划购买回购股份的价格为4.86元/股。 证券代码：603135 证券简称：中重科技 公告编号：202 ...

1. Reported Industry Investment Rating - No information provided in the given content 2. Core Viewpoints of the Report - The company's 2026 Employee Stock Ownership Plan (Draft) shows management's confidence in future development and the core team's optimism about the market prospects of core business products [26]. - The company has set three - year (2026 - 2028) performance assessment targets for the employee stock ownership plan, aiming to achieve revenue of 1 billion yuan in 2026, 1.5 billion yuan in 2027, and 2 billion yuan in 2028, and考核利润 of 300 million yuan in 2026, 500 million yuan in 2027, and 800 million yuan in 2028 [26]. - With the approval of multiple core products, the company's existing business revenue is expected to grow significantly in 2026, and there will be explosive growth in 2027 and 2028 [28]. 3. Summary by Relevant Catalogs 3.1 Research Basic Situation - Research object: Taienkang [16] - Industry: Pharmaceutical commerce [16] - Reception time: January 29, 2026 [16] - Listed company reception personnel: Li Ting, Director, Deputy General Manager, and Secretary of the Board of Directors [16] 3.2 Detailed Research Institutions - Securities companies: Huatai Securities, China Merchants Securities, Ping An Securities, Zhongtai Securities, Founder Securities, Huachuang Securities, Cinda Securities, CITIC Securities Co., Ltd., Tianfeng Securities, Shenwan Hongyuan, Guotai Haitong, Industrial Securities, Guohai Securities, Huafu Securities, Huaxi Securities, Galaxy Securities [17][18][20] - Fund management companies: Dacheng, Huabao, Huian, Huatai - PineBridge Fund, China Asset Management, Galaxy, Jianxin, Hangzhou Youyizeng Private Equity, Puyin AXA, Anxin, Hehe (Beijing) Private Equity, Morgan Stanley Fund Management (China), Hainan Ling Private Equity, Guoshou Anbao [17][18][19] - Asset management companies: Yong'an Guofu, Shanghai Yuxiu, Guangdong Hongyi, Huafu Securities, Zhongyin International Securities Co., Ltd. Asset Management, Ping An Insurance Asset Management, Fushun Asset Management (Shanghai), Zhonghuili Asset Management, Shanghai Qingding, Beijing Hanhe and Hanhua [18][19][20] - Investment companies: Shanghai Hengfu, Shanghai Zige, Zhejiang Yiheng, Beijing Zhuoyu, Shanghai Guanche [18][19] - Others: Western Medicine, Dongfang Investment Consulting, Dongcai Medicine, Hwa Site Asset Management, Northeast Medicine, Dongfang Medicine, Xiangwang Fund [18][19][20] 3.3 Research Institution Proportion - No information provided in the given content 3.4 Main Content Data - **Employee Stock Ownership Plan** - Fund - raising: The total amount of funds to be raised is 33.608 million yuan, with no more than 145 participants including directors, senior managers, and core employees, and all funds come from employees' legal salaries and self - raised funds [26]. - Assessment targets: From 2026 - 2028, the assessment indicators are revenue and考核利润 (deducted non - recurring profit and loss attributable to the parent + R & D expenses - investment income from associated and joint - venture enterprises - share - based payment expenses) [26]. - Incentive form: Employee stock ownership plan, employees need to contribute funds first and obtain shares through non - trading transfer [26]. - Unlock ratio: Unlock in three phases from 2026 - 2028, with 40%, 40%, and 20% respectively [28]. - Incentive shares: Approximately 1.98 million shares, sourced from the company's previous share repurchases [28]. - **Revenue and Profit Targets** - The company's existing products such as "Aitingjiu" for sexual health, "Wolitin" for ophthalmology, and Chinese patent medicines will maintain stable income [28]. - Multiple core products will be approved or applied for, including "Aitinglie" non - finasteride - tadalafil compound capsule (domestic first imitation) approved in December 2025, lidocaine - prilocaine aerosol (domestic first imitation) expected to be accepted by the drug administration soon, compound sodium sulfate tablets (domestic first imitation) expected to be approved in the first half of 2026, Heweizhengchang Pills (domestic exclusive) for localized production registration expected to be approved in the first half of 2026, and pilocarpine hydrochloride eye drops for presbyopia (domestic first imitation) expected to be approved in the second half of 2026 [28]. - **Heweizhengchang Pills Localized Production** - Since the second half of 2025, the company has carried out brand promotion in traditional advantageous regions such as Guangdong, Guangxi, and Fujian through platforms like Focus Media, Xiaohongshu, and Douyin [28]. - Actively expand third - party terminal channels such as clinics and Internet hospitals, and increase investment in online platforms such as Douyin, JD, and Tmall. Sales on the Douyin platform have increased significantly in January [28]. - After the domestic localization of Heweizhengchang Pills, multiple product specifications will be added to meet different needs and maintain the price system, with good sales expected in the first and second quarters of this year [28]. - **CKBA for Alzheimer's Disease** - Developed from AKBA, a natural triterpenoid compound from frankincense, CKBA can specifically target MFE - 2, a key metabolic enzyme in the peroxisomal β - oxidation pathway, maintaining lipid metabolism homeostasis in microglia and inhibiting the release of pro - inflammatory factors [28][29]. - Animal experiments show that oral CKBA can cross the blood - brain barrier, has no obvious toxic side effects, and has multiple therapeutic effects in Alzheimer's disease model mice [29]. - **Commercialization Preparation for New Products** - Increase brand promotion investment, cooperate with Meituan in addition to existing channels, and the sales on online platforms such as Meituan, Tmall, JD, and Douyin are increasing [29]. - Establish a specialized third - party terminal team to develop clinic and Internet hospital channels and adjust the sales team [29]. - For specific products, promote the inclusion of compound sodium sulfate tablets in medical insurance after approval; start medical insurance - related work for non - finasteride - tadalafil compound capsules, and continue in - depth brand promotion [30]. - **Progress of Child Vitiligo and Rosacea** - Rosacea may progress faster and is expected to be the first indication for CKBA to submit a registration application. The company aims to complete Phase III clinical trials by the end of 2027 [30]. - Child vitiligo Phase II clinical trials aim to enroll the first patient in March - April 2026 and basically complete Phase II clinical trials in the first half of 2027 [31]. - **Overseas Market of Child Vitiligo** - The company focuses on the domestic registration and listing of child vitiligo in 2 - 12 - year - old children. There is currently no approved product globally, and the company plans to start the IND application for the US FDA this year [32].

Summary of the Conference Call for Guangdong Tianen Pharmaceutical Co., Ltd. Company Overview - Guangdong Tianen Pharmaceutical Co., Ltd. specializes in the research, production, and sales of pharmaceuticals, with key products including Hewei Zhengchang Wan, "Woliting" Lecithin Iodine Tablets, and "Aiting Jiu" Dapoxetine Hydrochloride Tablets. The company was established in 1999 and has developed a significant sales network over 20 years [3][3][3]. Key Points Discussed Employee Stock Ownership Plan - The company disclosed a draft for the 2026 Employee Stock Ownership Plan, aiming to raise a total of 33.608 million yuan, involving up to 145 participants including directors and core employees. The plan reflects management's confidence in future growth and the market potential of core business products [12][12][12]. Performance Targets - The performance assessment period for the employee stock plan is set from 2026 to 2028, with specific targets: - Revenue: 1 billion yuan in 2026, 1.5 billion yuan in 2027, and 2 billion yuan in 2028 - Profit: 300 million yuan in 2026, 500 million yuan in 2027, and 800 million yuan in 2028 [15][15][15]. Product Development and Approval - The company expects multiple core products to be approved or submitted for approval, including: - "Aiting Lie" Finasteride and Tadalafil Compound Capsules (first domestic generic) approved in December 2025 - Lidocaine and Prilocaine Aerosol (first domestic generic) nearing regulatory submission - Compound Sodium Sulfate Tablets (first domestic generic) expected approval in H1 2026 - Localization of Hewei Zhengchang Wan production expected to be approved in H1 2026 - Pilocarpine Eye Drops for presbyopia (first domestic generic) anticipated approval in H2 2026 [18][19][19]. Marketing and Sales Strategy - The company has initiated brand promotion efforts in key regions and expanded online sales through platforms like Douyin and JD.com. The localized production of Hewei Zhengchang Wan is expected to enhance sales, with good performance anticipated in Q1 and Q2 of the current year [20][20][20]. Alzheimer's Disease Research - The company is developing CKBA for Alzheimer's disease, focusing on a compound derived from traditional Chinese medicine. CKBA has shown promising results in animal models, demonstrating cognitive improvement and neuroprotection [21][22][22]. Future Product Launches - The company plans to enhance brand promotion and has established a dedicated team for third-party channels, including clinics and internet hospitals. The approval of Compound Sodium Sulfate Tablets will be followed by efforts to include it in medical insurance [23][24][24]. Clinical Trials for Skin Conditions - The company is prioritizing the registration of treatments for pediatric vitiligo and rosacea, with rosacea expected to progress faster due to its shorter treatment cycle. The market potential for rosacea is significant, with over 50 million patients in China [25][26][27]. International Market Exploration - The company aims to explore overseas markets for CKBA, particularly in the pediatric vitiligo segment, where there are currently no approved treatments. Plans to initiate IND applications with the FDA are underway [27][27][27]. Additional Notes - The conference highlighted the company's commitment to innovation and growth in the pharmaceutical sector, with a focus on integrating research, production, and sales [3][3][3]. - The management emphasized the importance of maintaining a robust pipeline of products and adapting to market needs through strategic marketing and sales initiatives [20][20][20].

Group 1: Investor Relations Activity - The investor relations activity involved specific targeted research with participation from various fund management companies and securities firms [2][3]. - The meeting was held online on a Thursday morning, with a duration of 50 minutes [2]. Group 2: Employee Stock Ownership Plan - The company disclosed a draft for an employee stock ownership plan aiming to raise a total of CNY 33.608 million, involving directors, senior management, and core employees [3]. - The performance assessment period for the plan is set from 2026 to 2028, with specific revenue and profit targets: - Revenue targets: CNY 1 billion in 2026, CNY 1.5 billion in 2027, and CNY 2 billion in 2028 - Profit targets: CNY 300 million in 2026, CNY 500 million in 2027, and CNY 800 million in 2028 [3][4]. Group 3: Product Development and Market Strategy - The company has several core products expected to be approved or submitted for approval, including "Aitinglie" and "Lidocaine" aerosol, with anticipated revenue growth from existing products and new approvals [4][5]. - The company is actively promoting the "Hewei Zhengchang Wan" product through various media channels and expanding its sales through clinics and online platforms [5][8]. - The company plans to enhance brand promotion and has established a dedicated team for third-party channels, focusing on clinics and internet hospitals [8]. Group 4: Alzheimer's Disease Research - The company is developing CKBA for Alzheimer's disease, which has shown promising results in animal models, including cognitive improvement and reduced neuroinflammation [6][7]. - CKBA's mechanism targets MFE-2, a key enzyme in lipid metabolism, which is crucial for maintaining the homeostasis of microglial cells [7]. Group 5: Clinical Trials and Market Potential - The company is prioritizing the registration of treatments for pediatric vitiligo and rosacea, with rosacea expected to progress faster due to a shorter treatment cycle [9][10]. - The domestic market for pediatric vitiligo is significant, with no existing treatments approved by the FDA, indicating potential for market expansion [11]. Group 6: Forward-Looking Statements - The report includes forward-looking statements regarding future plans and performance forecasts, emphasizing the need for investors to recognize associated risks [11].

Summary of Conference Call Records Company Overview - **Company**: Yirui Technology (奕瑞科技) - **Industry**: Medical Equipment, XR Devices, Semiconductor Packaging Key Points Financial Performance - **2025 Revenue**: 22.99 billion, YOY +25.53% [1] - **Net Profit**: 6.61 billion, YOY +42.15% [1] - **Net Profit (Excluding Non-recurring Items)**: 6.27 billion, YOY +42.89% [1] - **Q4 2025 Revenue**: 7.50 billion, YOY +57.79% [1] - **Q4 2025 Net Profit**: 1.91 billion, YOY +154.16% [1] - **Q4 2025 Net Profit (Excluding Non-recurring Items)**: 1.87 billion, YOY +253.39% [1] - **Performance**: Q4 2025 revenue reached a record high, indicating a stabilization and recovery in profitability [1][2] Growth Drivers - **Domestic Medical Equipment Policy**: The old-for-new policy has supported a rebound in downstream demand, accelerating growth in the medical imaging business [2] - **Partnerships**: Established stable cooperation with leading global dental equipment manufacturers, becoming a major supplier in the Korean dental CBCT market [2] - **Lithium Battery Expansion**: Increased production by companies like CATL has led to a rise in demand for chip packaging testing, driving growth in industrial testing for lithium batteries and PCBs [2] - **New Core Components**: Significant growth in high-voltage generators and combination ray sources [2] - **Silicon-based OLED Backplane**: Mass production has begun contributing to revenue [2] Market Outlook - **2026 Industry Trends**: Anticipated upward trend in industry prosperity, with expectations for the company's global market share to increase alongside the growth of silicon-based OLED backplanes [2] - **Related Company IPO**: The upcoming IPO of Visionary Technology (视涯科技) is expected to drive rapid demand for silicon-based OLED backplanes in XR devices [2] Employee Incentives - **Employee Stock Ownership Plan**: Announced on January 24, 2026, aiming to raise up to 100 million, involving up to 150 employees, including key executives [3] - **Performance Targets**: The plan sets a profit growth target of 15% based on 2025 net profit, with an ambitious target of 25% [3] Risks - **Investment Risks**: Potential underperformance in expansion plans and slower-than-expected development in the XR device industry [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603260 证券简称：合盛硅业 公告编号：2026-007 ■ 一、本期员工持股计划基本情况 合盛硅业股份有限公司（以下简称"公司"或"合盛硅业"）于2025年10月28日召开第四届董事会第十次会 议、第四届监事会第九次会议审议通过了《关于〈合盛硅业股份有限公司2025年员工持股计划（草 案）〉及其摘要的议案》等2025年员工持股计划相关议案。上述议案后经公司于2025年11月17日召开的 2025年第三次临时股东会审议通过。具体内容详见2025年10月31日、11月18日在上海证券交易所网站 （www.sse.com.cn）披露的相关公告。 本员工持股计划股票来源为公司回购专用账户回购的合盛硅业A股普通股股票。本员工持股计划拟持有 的标的股票数量不超过330.00万股，由公司回购专用证券账户以47.05元/股的价格非交易过户至本员工 持股计划专用证券账户。 二、本期员工持股计划完成股票过户的情况 公司于2026年1月28日收到中国证券登记结算有限责任公司上海分公司出具的《证券过户登记确认 书》，公司回购专用证券账户持有的204.76万股公司股票已 ...

证券代码：002384 证券简称：东山精密 公告编号：2026-001 苏州东山精密制造股份有限公司 登录新浪财经APP 搜索【信披】查看更多考评等级 第六届董事会第三十一次会议 决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 苏州东山精密制造股份有限公司（以下简称"公司"）第六届董事会第三十一次会议（以下简称"会议"） 通知于2026年1月23日以专人送达、邮件等方式发出，会议于2026年1月28日在公司以现场结合通讯的方 式召开。会议应到董事11人，实到董事11人。公司高级管理人员列席了会议。会议由公司董事长袁永刚 先生主持。本次会议的召开符合《公司法》《公司章程》等有关法律法规规定，会议经过讨论审议，以 书面投票表决的方式通过以下决议： 一、审议通过《关于公司〈2026年员工持股计划（草案）〉及其摘要的议案》，并同意将该议案提交股 东会审议。 表决结果：9票同意、0票反对、0票弃权（关联董事袁永刚先生、袁永峰先生回避表决）。 本议案已经公司董事会薪酬与考核委员会审议通过。 根据《公司法》《证券法》《关于上市公司实施员工持股计划试点的指导意见》《 ...

证券代码：605090 证券简称：九丰能源 公告编号：2026-005 江西九丰能源股份有限公司2025年员工持股计划第一次持有人会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、持有人会议召开情况 江西九丰能源股份有限公司（以下简称"公司"）2025年员工持股计划（以下简称"本员工持股计划"）第 一次持有人会议于2026年1月28日（星期三）以现场结合通讯表决方式召开。本次会议由公司董事、副 总经理兼董事会秘书黄博先生召集并主持，出席本次会议的持有人共27人，代表本员工持股计划有表决 权份额7,552.00万份，占本员工持股计划已认购总份额的100.00%。会议的召集、召开和表决程序符合 公司《2025年员工持股计划》《2025年员工持股计划管理办法》等相关规定。 二、持有人会议审议情况 经与会持有人认真审议，本次会议逐项表决通过了以下决议： （一）审议通过《关于设立2025年员工持股计划管理委员会的议案》 为保证员工持股计划的顺利进行，保障持有人的合法权益，根据公司《2025年员工持股计划》《2025年 员 ...

在产品管线方面，根据公司1月22日披露的公告显示，公司核心在研产品CKBA乳膏针对儿童白癜风的II 期临床试验申请已获得批准，前期探索性研究显示其联合光疗方案疗效显著，该II期试验计划于2026年 第一季度启动首例患者入组，并计划同期启动FDA临床申报。 与此同时，公司仿制药业务迎来收获期，根据公司2025年11月21日披露的投资者关系活动记录表显示， 公司复方硫酸钠片(国内首仿)与和胃整肠丸(国内独家)的本地化生产注册均预计在2026年上半年获批； 老花眼用药盐酸毛果芸香碱滴眼液(国内首仿)则预计在2026年下半年获批。 根据公告，本次员工持股计划的资金来源为员工合法薪酬及自筹资金，公司不存在向持有人提供财务资 助或为其贷款提供担保的情形。计划购买回购股份的价格为16.93元/股，拟持有的标的股票数量不超过 198.51万股，约占公司总股本的0.47%。 草案明确了2026年至2028年三个年度的业绩考核目标。2026年度，营业收入目标值为10.00亿元，触发 值为9.00亿元；考核利润目标值为3.00亿元，触发值为2.70亿元。2027年度，营业收入目标值提升至 15.00亿元，触发值为13.50亿元；考 ...

Group 1 - The core point of the news is that Guangdong Taiankang Pharmaceutical Co., Ltd. has disclosed its employee stock ownership plan for 2026, aiming to raise a maximum of 33.608 million yuan, with participation from up to 145 individuals including directors, senior management, and key employees [1] - The employee stock ownership plan is closely tied to the company's performance over the next three years, with assessment indicators including both "operating revenue" and "assessed profit," targeting significant growth [1][2] - The plan outlines specific unlock periods and performance targets, with the first unlock period set for 2026, requiring operating revenue to reach 1 billion yuan and assessed profit to hit 270 million yuan [2] Group 2 - The company is expected to see significant revenue growth as several core products are set to be approved or submitted for approval, including a domestic first generic of lidocaine and prilocaine aerosol, which is anticipated to complete registration by 2026 [2][3] - Participants in the employee stock ownership plan are required to use their own funds for subscription, with shares sourced from the company's repurchased stock at a price of 16.93 yuan per share [3] - The company believes that this long-term mechanism of employee stock ownership will effectively motivate the core team's enthusiasm and creativity, promoting the research, market promotion, and sales of core products to ensure the achievement of high growth targets [3]